We are live on ! Find out more
JP

John Paulson Paulson & Co

AUM $2.58B
1-Year Est. Return 68.51%
 

John Paulson is the founder of Paulson & Co., a firm that became world-famous for profits related to the 2007–2008 housing and credit crisis. Beyond that landmark trade, the firm has pursued merger arbitrage, event-driven, and opportunistic credit and equity strategies. Paulson remains one of the most recognized names in modern hedge fund history.

This Fund
S&P 500
This Quarter Est. Return
-3.7%
1 Year Est. Return
+68.51%
3 Year Est. Return
+251.48%
5 Year Est. Return
+229.81%
10 Year Est. Return
+881.28%
AUM
$7.93B
AUM Growth
-$1.29B
Cap. Flow
-$532M
Cap. Flow %
-6.7%
Top 10 Hldgs %
63.38%
Holding
120
New
26
Increased
14
Reduced
40
Closed
18

Sector Composition

Rank Sector Weight
1 Healthcare 52.69%
2 Consumer Discretionary 11.7%
3 Communication Services 5.62%
4 Technology 4.96%
5 Materials 4.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KMDA icon
76
Kamada
KMDA
$475M
$3.98M 0.05%
730,800
GPRO icon
77
PUT
GoPro
GPRO
$116M
$3.48M 0.04%
+400,000
New +$4.59M
CBOE icon
78
Cboe Global Markets
CBOE
$31.4B
$2.84M 0.04%
38,412
INSM icon
79
Insmed
INSM
$27.5B
$2.71M 0.03%
205,200
BCRX icon
80
CALL
BioCryst Pharmaceuticals
BCRX
$2.44B
$2.22M 0.03%
+350,000
New +$1.82M
DG icon
81
Dollar General
DG
$27.2B
$2.19M 0.03%
+29,600
New +$2.16M
MJN
82
DELISTED
Mead Johnson Nutrition Company
MJN
$2.18M 0.03%
30,800
-47,700
-61% -$3.56M
FDX icon
83
FedEx
FDX
$76.9B
$2.05M 0.03%
11,000
-95,800
-90% -$17.6M
SHOP icon
84
Shopify
SHOP
$192B
$1.75M 0.02%
407,000
-335,000
-45% -$1.41M
WCIC
85
DELISTED
WCI Communities, Inc.
WCIC
$1.64M 0.02%
70,000
ALDR
86
DELISTED
Alder Biopharmaceuticals
ALDR
$1.54M 0.02%
74,000
ESPR
87
DELISTED
Esperion Therapeutics
ESPR
$1.28M 0.02%
102,000
TVTX icon
88
Travere Therapeutics
TVTX
$6.19B
$1.04M 0.01%
+55,000
New +$1.12M
AKAO
89
DELISTED
Achaogen Inc
AKAO
$944K 0.01%
+72,500
New +$497K
RIGL icon
90
Rigel Pharmaceuticals
RIGL
$857M
$923K 0.01%
38,770
-41,730
-52% -$1.2M
ALNY icon
91
Alnylam Pharmaceuticals
ALNY
$31.6B
$723K 0.01%
19,300
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$687K 0.01%
174,000
PBYI icon
93
Puma Biotechnology
PBYI
$477M
$482K 0.01%
15,690
-68,810
-81% -$2.98M
BCRX icon
94
BioCryst Pharmaceuticals
BCRX
$2.44B
$333K ﹤0.01%
52,600
-310,500
-86% -$1.62M
ARDM
95
DELISTED
Aradigm Corp Common Stock
ARDM
$308K ﹤0.01%
192,727
+45,809
+31% +$201K
OSG
96
DELISTED
Overseas Shipholding Group Inc.
OSG
$274K ﹤0.01%
71,602
+26,463
+59% +$193K
CLDX icon
97
Celldex Therapeutics
CLDX
$3.17B
$251K ﹤0.01%
4,720
LILA icon
98
Liberty Latin America Class A
LILA
$1.66B
$110K ﹤0.01%
7,793
NVDQ
99
PUT
DELISTED
Novadaq Technologies Inc.
NVDQ
$25K ﹤0.01%
+500,000
New +$4.54M
CVS icon
100
CVS Health
CVS
$119B
-122,200
Closed -$10.9M

Similar funds

John Paulson's Q4 2016 Portfolio in Review

As of Q4 2016, John Paulson held 120 positions worth $7.93B, down 14% from $9.23B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

John Paulson withdrew a net $532M in Q4 2016, closing 18 positions and reducing 40 holdings. Its most notable exit was T-Mobile US, an estimated $44.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 58% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, John Paulson opened a new position in Time Warner Inc worth $276M.

  • John Paulson's largest Q4 2016 buy was Time Warner Inc: 2,855,900 shares worth $276M.
  • John Paulson added most to International Tower Hill Mines in Q4 2016, an estimated $20.7M increase.
  • John Paulson's biggest Q4 2016 reduction was American International, cutting an estimated $267M.
  • John Paulson fully exited T-Mobile US in Q4 2016, selling an estimated $44.6M.
  • John Paulson's ten largest holdings make up 63% of its $7.93B portfolio in Q4 2016.
  • John Paulson opened 26 new positions and closed 18 in Q4 2016.
  • John Paulson's portfolio value fell 14% quarter-over-quarter to $7.93B.

Based on Paulson & Co's 13F filing for Q4 2016, filed 14 Feb 2017.